Profile data is unavailable for this security.
About the company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
- Revenue in DKK (TTM)22.50bn
- Net income in DKK9.31bn
- Incorporated1998
- Employees2.68k
- LocationGenmab A/SCarl Jacobsens Vej 30VALBY 2500DenmarkDNK
- Phone+45 70202728
- Fax+45 70202729
- Websitehttps://www.genmab.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zealand Pharma A/S | 9.16bn | 6.54bn | 29.98bn | 440.00 | 4.61 | 1.94 | 4.56 | 3.27 | 91.00 | 91.00 | 129.24 | 215.72 | 0.6929 | 3.05 | 75.81 | 27,328,360.00 | 49.52 | -32.33 | 52.34 | -36.49 | 99.99 | 95.31 | 71.47 | -515.03 | 14.10 | -- | 0.0261 | -- | -81.71 | 8.69 | -53.30 | -- | -10.98 | -- |
| BACHEM HOLDING AG | 5.54bn | 1.10bn | 40.97bn | 2.29k | 37.18 | 3.68 | 28.87 | 7.39 | 1.80 | 1.80 | 9.07 | 18.14 | 0.3733 | 1.05 | 4.37 | 307,174.00 | 7.39 | 8.26 | 8.60 | 9.44 | 31.23 | 31.55 | 19.79 | 20.06 | 0.781 | 12.09 | 0.0428 | 52.54 | 4.84 | 14.05 | 7.50 | 17.29 | 56.91 | 7.21 |
| Abivax SA | 0.00 | -1.46bn | 59.67bn | 69.00 | -- | -- | -- | -- | -3.09 | -3.09 | 0.00 | -0.7607 | 0.00 | -- | -- | 0.00 | -96.69 | -65.05 | -184.49 | -98.10 | -- | -- | -- | -- | -- | -21.71 | 2.33 | -- | -- | -- | -19.29 | -- | -7.33 | -- |
| Qiagen NV | 13.13bn | 2.67bn | 66.47bn | 5.65k | 25.73 | 2.94 | 17.10 | 5.06 | 1.68 | 1.68 | 8.24 | 14.67 | 0.3488 | 2.66 | 5.45 | 310,786.60 | 7.09 | 5.89 | 7.77 | 6.96 | 62.97 | 63.60 | 20.33 | 17.13 | 3.31 | -- | 0.3045 | -- | 5.65 | 2.25 | 408.28 | 3.42 | -7.40 | -- |
| Eurofins Scientific SE | 54.51bn | 3.55bn | 91.79bn | 65.00k | 26.55 | 2.64 | 11.14 | 1.68 | 2.54 | 2.54 | 38.86 | 25.54 | 0.6671 | 40.83 | 5.17 | -- | 4.32 | 6.78 | 5.48 | 8.46 | 21.40 | 23.08 | 6.48 | 10.10 | 1.03 | 6.34 | 0.492 | 21.89 | 4.96 | 6.05 | -25.14 | -6.70 | 8.60 | 1.15 |
| Genmab A/S | 22.50bn | 9.31bn | 124.71bn | 2.68k | 13.15 | 3.31 | 12.83 | 5.54 | 147.58 | 147.58 | 356.95 | 586.68 | 0.5535 | 16.68 | 3.60 | 8,389,996.00 | 22.89 | 17.70 | 25.72 | 19.07 | 94.27 | -- | 41.35 | 35.77 | 6.01 | -- | 0.0241 | -- | 30.57 | 31.16 | 80.10 | 28.50 | 21.52 | -- |
| Lonza Group AG | 53.41bn | 7.43bn | 296.69bn | 19.77k | 39.92 | 3.88 | 23.32 | 5.56 | 12.94 | 13.51 | 93.02 | 133.07 | 0.3375 | 2.45 | 4.32 | 330,332.30 | 4.70 | 4.70 | 5.78 | 5.72 | 36.15 | 37.28 | 13.92 | 13.02 | 1.77 | 7.77 | 0.313 | 34.17 | -0.6541 | 7.70 | 42.92 | 4.48 | 7.13 | 10.76 |
| argenx SE | 22.64bn | 9.63bn | 328.34bn | 1.60k | 36.53 | -- | -- | 14.50 | 19.44 | 19.44 | 45.86 | -- | -- | -- | -- | 1,895,338.00 | -- | -7.11 | -- | -7.96 | 89.63 | -- | 42.54 | -27.22 | -- | -- | -- | -- | 78.60 | 94.61 | 382.34 | -- | 7.88 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Orbis Investment Management Ltd.as of 30 Sep 2025 | 2.62m | 4.08% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 2.31m | 3.60% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 1.35m | 2.10% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.22m | 1.91% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 1.20m | 1.87% |
| Schroder Investment Management Ltd.as of 31 Dec 2025 | 770.34k | 1.20% |
| BlackRock Advisors (UK) Ltd.as of 09 Jan 2026 | 690.95k | 1.08% |
| Geode Capital Management LLCas of 05 Feb 2026 | 686.80k | 1.07% |
| Harding Loevner LPas of 31 Dec 2025 | 631.97k | 0.98% |
| Amundi Asset Management SASU (Investment Management)as of 30 Jan 2026 | 457.27k | 0.71% |
